Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VAGA-9001a + MABH-9002b
- Development stage
- Phase 2
- Lead developer
- Daiichi Sankyo
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**VAGA-9001a + MABH-9002b** is the defined antigen-plus-adjuvant composition of Daiichi Sankyo's investigational RSV vaccine candidate VN-0200. VAGA-9001a is an RSV fusion glycoprotein antigen intended to induce RSV-specific neutralizing antibody and cellular immune responses, while MABH-9002b is a beta-glucan-CpG adjuvant intended to enhance innate and adaptive immune activation. The vaccine has been evaluated as a two-dose intramuscular preventive regimen in healthy Japanese older adults, including a randomized Phase 2 dose-finding study assessing immunogenicity, safety, and tolerability. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12013440/))
- Other names
- VN0200VN-0200VN 0200
02
Targets
RSV F (Respiratory syncytial virus fusion protein)TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on VAGA-9001a + MABH-9002b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VAGA-9001a + MABH-9002b.